Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non–Small Cell Lung Cancer

To the Editor We are writing to express some concerns about the methodology and interpretation of a recent study by Feng et al about treatment of pretreated epidermal growth factor receptor (EGFR)–variant non–small cell lung cancer (NSCLC).1